Rajesh C. Shrotriya

Dr. Rajesh C. Shrotriya, M.D., served as the Chairman and Chief Executive Officer of Spectrum Pharmaceuticals, Inc. from August 2002 to December 17, 2017 and served as its President from September 2000 to April 17, 2014. From September 2000 to August 2002, Dr. Shrotriya served as the Chief Operating Officer of Spectrum. He served as an Executive VP and Chief Scientific Officer for SuperGen, Inc. from November 1996 to August 2000 and its Senior VP and Special Assistant to the President from November 1996 to May 1997.

From August 1994 to October 1996, Dr. Shrotriya served as VP, Medical Affairs and VP, Chief Medical Officer of MGI Pharma, Inc. Dr. Shrotriya was a Director of Spectrum Pharmaceuticals, Inc. from June 2001 until June 18, 2018. He spent 18 years at Bristol-Myers Squibb Company in a variety of positions as Executive Director, Worldwide CNS Clinical Research. Dr. Shrotriya held various positions at Hoechst Pharmaceuticals and served as its Medical Advisor. He was an attending physician and held a courtesy appointment at St. Joseph Hospital in Stamford, Connecticut. He served as the President and Chief Operating Officer of NeoTherapeutics Inc., since September 2000 and served as its Chief Executive Officer since August 2002. Dr. Shrotriya served as Chairman of the Board at NeoOncoRx, Inc.

He has been an Independent Director of CASI Pharmaceuticals, Inc. since September 2014. He served as a Director of Antares Pharma Inc., since April 13, 2004. In addition, he received a certificate for Advanced Biomedical Research Management from Harvard University. Dr. Shrotriya received his M.D. degree from Grant Medical College, Bombay, India, in 1974; his D.T.C.D. (Post Graduate Diploma in Chest Diseases) degree from Delhi University, V.P. Chest Institute, Delhi, India, in 1971; M.B.B.S. and Bachelor of Surgery degree from the Armed Forces Medical College, Poona, India, in 1967 and a B.S. with Chemistry Degree from Agra University, Aligarh, India, in 1962.